Jean Bergeron
- Formation
-
MD
MSc
FRCPC
Aucune offre active
Autres opportunités de carrière
- Axe principal
- Métabolisme, santé vasculaire et rénale
- Adresse
- 2705, boulevard Laurier, G-00224
Québec (Québec)
CANADA G1V 4G2 - Téléphone
- +1 418-525-4444, poste 42162
- Télécopieur
- +1 418-654-2134
- Courriel
- Jean.Bergeron@crchul.ulaval.ca
En tant que clinicien et scientifique, Dr Bergeron s’intéresse à l’expression des hyperlipidémies primaires, à la validation de nouveaux marqueurs métaboliques sanguins (apoB, hs-CRP,…) comme outil de stratification du risque CV en pratique clinique courante et à la myopathie associée aux statines. Il est investigateur pour de nombreux essais cliniques utilisant de nouveaux agents hypolipidémiants, diverses thérapies contre le syndrome métabolique ou le diabète de type 2 et il possède une expertise clinique particulière concernant les dyslipidémies liées aux maladies rénales et à la transplantation.
Publications récentes (voir toutes les publications de ce chercheur)
Borel AL, Nazare JA, Smith J, Almeras N, Tremblay A, Bergeron J, Poirier P, Despres JP. Visceral and Not Subcutaneous Abdominal Adiposity Reduction Drives the Benefits of a 1-Year Lifestyle Modification Program. Obesity (Silver Spring, Md.),
2012. Epub
Faucher G, Guenard F, Bouchard L, Garneau V, Turcot V, Houde A, Tchernof A, Bergeron J, Deshaies Y, Hould FS, Lebel S, Marceau P, Vohl MC. Genetic contribution to C-reactive protein levels in severe obesity. Molecular genetics and metabolism,
2011. Epub
Riou ME, Doucet E, Provencher V, Weisnagel SJ, Piche ME, Dube MC, Bergeron J, Lemieux S. Influence of Physical Activity Participation on the Associations between Eating Behaviour Traits and Body Mass Index in Healthy Postmenopausal Women. Journal of obesity,
2011. 2011:
Dube MC, Lemieux S, Piche ME, Corneau L, Bergeron J, Riou ME, Weisnagel SJ. The contribution of visceral adiposity and mid-thigh fat-rich muscle to the metabolic profile in postmenopausal women. Obesity (Silver Spring, Md.),
2011. 19: 953-9
Lemieux S, Bedard A, Piche ME, Weisnagel SJ, Corneau L, Bergeron J. Visceral adipose tissue accumulation and cardiovascular disease risk profile in postmenopausal women with impaired glucose tolerance or type 2 diabetes. Clinical endocrinology,
2011. 74: 340-5
Lapointe A, Tchernof A, Lamarche B, Piche ME, Weisnagel J, Bergeron J, Lemieux S. Plasma adiponectin concentration is strongly associated with VLDL-TG catabolism in postmenopausal women. Nutrition, metabolism, and cardiovascular diseases : NMCD
,
2011. 21: 254-60
Borel AL, Nazare JA, Smith J, Almeras N, Tremblay A, Bergeron J, Poirier P, Despres JP. Improvement in insulin sensitivity following a 1-year lifestyle intervention program in viscerally obese men: contribution of abdominal adiposity. Metabolism: clinical and experimental,
2011. Epub
Mancini GB, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, Gupta M, Hegele RA, Ng D, Pope J. Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a canadian working group consensus conference. The Canadian journal of cardiology,
2011. 27: 635-62
Gangloff A, Bergeron J, Couture P, Martins R, Hegele RA, Gagne C. A novel mutation of apolipoprotein B in a French Canadian family with homozygous hypobetalipoproteinemia. Journal of clinical lipidology,
2011. 5: 414-7
Bouchard L, Vohl MC, Lebel S, Hould FS, Marceau P, Bergeron J, Perusse L, Mauriege P. Contribution of genetic and metabolic syndrome to omental adipose tissue PAI-1 gene mRNA and plasma levels in obesity. Obesity surgery : the official journal of the American Society for Bariatric Surgery and of the Obesity Surgery Society of Australia and New Zealand,
2010. 20: 492-9
